Cell line · CVCL_0393
Papers104
1 to 20 of 104
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Low-Density Lipoprotein Receptor-Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| COPS7B Drives Malignant Progression of Glioblastoma Through Translational Upregulation of the Downstream Functional Effector CLU. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exploring Disulfide Bridge as a Tool to Improve Pioglitazone's Neuroprotective Potential: Toward the Development of Prolonged-Acting MAO-B/PPARγ Modulators. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Potent Anti-Glioblastoma Effects of Next-Generation MNK Inhibitors. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Feasibility and optimal imaging time window for intraperitoneal versus intravenous injection of a macrocyclic gadolinium-based contrast agent in mice. | J Int Med Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia-induced circSPECC1 drives temozolomide resistance in glioblastoma via IGF2BP2-mediated PGK1 mRNA stabilization. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CUDC-907 inhibits glioblastoma and enhances glioblastoma sensitivity to temozolomide by inhibiting DNA damage repair. | Genes Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacological Ascorbate Restrains Epithelial-Mesenchymal Transition and Invasion in Glioblastoma Cells via Extracellular H2O2 Generation. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. | Cancer Immunol Immunother | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AI-driven network pharmacology and multi-omics validation identify KCNH2 as a prognostic biomarker and candidate therapeutic vulnerability of Acorus tatarinowii in glioblastoma. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CREsted: modeling genomic and synthetic cell-type-specific enhancers across tissues and species. | Nat Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening. | Macromol Biosci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cells. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lipid Droplet-Localized Spindle Apparatus Coiled-Coil Protein 1 Regulates Lipid Droplet Distribution. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2'-deoxyuridine (EdU). | Proc Natl Acad Sci U S A | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0393/papers